Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin

Cancer Cell

Volumn 3, Issue 6, 2003, Pages 589-601

  Hamano, Yuki ^a   Zeisberg, Michael ^a   Sugimoto, Hikaru ^a   Lively, Julie C ^a,b   Maeshima, Yohei ^a   Yang, Changqing ^a   Hynes, Richard O ^b   Werb, Zena ^c   Sudhakar, Akulapalli ^a   Kalluri, Raghu ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA3 INTEGRIN; COLLAGEN TYPE 4; GELATINASE B; INTEGRIN; TUMSTATIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CIRCULATION; CONTROLLED STUDY; DEVELOPMENT; DISEASE ASSOCIATION; DRUG EFFECT; GENE DELETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SUPPLEMENTATION; TISSUE REPAIR; TUMOR GROWTH;

ANIMALIA;

EID: 10744223801     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00133-8     Document Type: Article

References (75)

1. Andrews K.L., Mudd J.L., Li C., Miner J.H. Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am. J. Pathol. 160:2002;721-730.
2. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:2000;737-744.
3. Bramhall S.R., Hallissey M.T., Whiting J., Scholefield J., Tierney G., Stuart R.C., Hawkins R.E., McCulloch P., Maughan T., Brown P.D.et al. Marimastat as maintenance therapy for patients with advanced gastric cancer. a randomised trial Br. J. Cancer. 86:2002;1864-1870.
4. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
5. Colorado P.C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., Volk R., Zamborsky E.D., Herman S., Ericksen M.B.et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 60:2000;2520-2526.
6. Cosgrove D., Meehan D.T., Grunkemeyer J.A., Kornak J.M., Sayers R., Hunter W.J., Samuelson G.C. Collagen COL4A3 knockout. a mouse model for autosomal Alport syndrome Genes Dev. 10:1996;2981-2992.
7. Czubayko F., Liaudet-Coopman E.D., Aigner A., Tuveson A.T., Berchem G.J., Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat. Med. 3:1997;1137-1140.
8. Derry C.J., Pusey C.D. Tissue-specific distribution of the Goodpasture antigen demonstrated by 2-D electrophoresis and western blotting. Nephrol. Dial. Transplant. 9:1994;355-361.
9. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer. 2:2002;161-174.
10. Eklund L., Piuhola J., Komulainen J., Sormunen R., Ongvarrasopone C., Fassler R., Muona A., Ilves M., Ruskoaho H., Takala T.E., Pihlajaniemi T. Lack of type XV collagen causes a skeletal myopathy and cardiovascular defects in mice. Proc. Natl. Acad. Sci. USA. 98:2001;1194-1199.
11. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., Cheresh D.A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell. 4:1999;915-924.
12. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog. Horm. Res. 55:2000;15-35.
13. Folkman J. Angiogenesis-dependent diseases. Semin. Oncol. 28:2001;536-542.
14. Folkman J., Kalluri R. Tumor angiogenesis. Holland J.F., Frei E. III, Bast R.C. Jr., Kufe D.W., Pollock R.E., Weichselbaum R.R. In Cancer Medicine. 6th Editon:2003;PC Decker Inc, Ontario, Canada. in press.
15. Frojdman K., Pelliniemi L.J., Virtanen I. Differential distribution of type IV collagen chains in the developing rat testis and ovary. Differentiation. 63:1998;125-130.
16. Fukai N., Eklund L., Marneros A.G., Oh S.P., Keene D.R., Tamarkin L., Niemela M., Ilves M., Li E., Pihlajaniemi T., Olsen B.R. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J. 21:2002;1535-1544.
17. Gabrielli A., Marchegiani G., Rupoli S., Ansuini G., Brocks D.G., Danieli G., Timpl R. Assessment of disease activity in essential cryoglobulinemia by serum levels of a basement membrane antigen, laminin. Arthritis Rheum. 31:1988;1558-1562.
18. Gunwar S., Ballester F., Kalluri R., Timoneda J., Chonko A.M., Edwards S.J., Noelken M.E., Hudson B.G. Glomerular basement membrane. Identification of dimeric subunits of the noncollagenous domain (hexamer) of collagen IV and the Goodpasture antigen. J. Biol. Chem. 266:1991;15318-15324.
19. Hamano Y., Grunkemeyer J.A., Sudhakar A., Zeisberg M., Cosgrove D., Morello R., Lee B., Sugimoto H., Kalluri R. Determinants of vascular permeability in the kidney glomerulus. J. Biol. Chem. 277:2002;31154-31162.
20. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
21. Hawighorst T., Velasco P., Streit M., Hong Y.K., Kyriakides T.R., Brown L.F., Bornstein P., Detmar M. Thrombospondin-2 plays a protective role in multistep carcinogenesis. a novel host anti-tumor defense mechanism EMBO J. 20:2001;2631-2640.
22. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N.R., Crystal R.G., Besmer P., Lyden D., Moore M.A.et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 109:2002;625-637.
23. Hodivala-Dilke K.M., McHugh K.P., Tsakiris D.A., Rayburn H., Crowley D., Ullman-Cullere M., Ross F.P., Coller B.S., Teitelbaum S., Hynes R.O. β3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 103:1999;229-238.
24. Hogemann B., Voss B., Pott G., Rauterberg J., Gerlach U. 7S collagen. a method for the measurement of serum concentrations in man Clin. Chim. Acta. 144:1984;1-10.
25. Hudson B.G., Reeders S.T., Tryggvason K. Type IV collagen. structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis J. Biol. Chem. 268:1993;26033-26036.
26. Hynes R.O. A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 8:2002;918-921. a.
27. Hynes R.O., Lively J.C., McCarty J.H., Taverna D., Xiao Q., Hodivala-Dilke K. Diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb. Symp. Quant. Biol. 67:2002;143-153. b.
28. Kahsai T.Z., Enders G.C., Gunwar S., Brunmark C., Wieslander J., Kalluri R., Zhou J., Noelken M.E., Hudson B.G. Seminiferous tubule basement membrane. Composition and organization of type IV collagen chains, and the linkage of α3(IV) and α5(IV) chains. J. Biol. Chem. 272:1997;17023-17032.
29. Kalluri R. Discovery of type IV collagen non collagenous domains as endogenous inhibitors of angiogenesis and tumor growth and novel integrin ligands. Cold Spring Harb. Symp. Quant. Biol. 67:2002;255-266.
30. Kalluri R., Cosgrove D. Assembly of type IV collagen. Insights from α3(IV) collagen-deficient mice. J. Biol. Chem. 275:2000;12719-12724.
31. Kalluri R., Sun M.J., Hudson B.G., Neilson E.G. The Goodpasture autoantigen. Structural delineation of two immunologically privileged epitopes on α3(IV) chain of type IV collagen. J. Biol. Chem. 271:1996;9062-9068.
32. Kalluri R., Danoff T.M., Okada H., Neilson E.G. Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J. Clin. Invest. 100:1997;2263-2275. a.
33. Kalluri R., Shield C.F., Todd P., Hudson B.G., Neilson E.G. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J. Clin. Invest. 99:1997;2470-2478. b.
34. Kamphaus G.D., Colorado P.C., Panka D.J., Hopfer H., Ramchandran R., Torre A., Maeshima Y., Mier J.W., Sukhatme V.P., Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275:2000;1209-1215.
35. Kashtan C.E. Alport syndrome and thin glomerular basement membrane disease. J. Am. Soc. Nephrol. 9:1998;1736-1750.
36. Kuhn K. Basement membrane (type IV) collagen. Matrix Biol. 14:1995;439-445.
37. Lawler J., Miao W.M., Duquette M., Bouck N., Bronson R.T., Hynes R.O. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am. J. Pathol. 159:2001;1949-1956.
38. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L.et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:2001;1194-1201.
39. Madri J.A. Extracellular matrix modulation of vascular cell behaviour. Transpl. Immunol. 5:1997;179-183.
40. Madri J.A., Pratt B.M. Endothelial cell-matrix interactions. in vitro models of angiogenesis J. Histochem. Cytochem. 34:1986;85-91.
41. Maeshima Y., Colorado P.C., Kalluri R. Two RGD-independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 275:2000;23745-23750. a.
42. Maeshima Y., Colorado P.C., Torre A., Holthaus K.A., Grunkemeyer J.A., Ericksen M.D., Hopfer H., Xiao Y., Stillman I.E., Kalluri R. Distinct anti-tumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem. 275:2000;21340-21348. b.
43. Maeshima Y., Manfredi M., Reimer C., Holthaus K.A., Hopfer H., Chandamuri B.R., Kharbanda S., Kalluri R. Identification of the anti-angiogenic site within vascular basement membrane derived tumstatin. J. Biol. Chem. 276:2001;15240-15248. a.
44. Maeshima Y., Yerramalla U.L., Dhanabal M., Holthaus K.A., Barbashov S., Kharbanda S., Reimer C., Manfredi M., Dickerson W.M., Kalluri R. Extracellular matrix-derived peptide binds to αvβ3 integrin and inhibits angiogenesis. J. Biol. Chem. 276:2001;31959-31968. b.
45. Maeshima Y., Sudhakar A., Lively J.C., Ueki K., Kharbanda S., Kahn C.R., Sonenberg N., Hynes R.O., Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science. 295:2002;140-143.
46. Maragoudakis M.E., Missirlis E., Karakiulakis G.D., Sarmonica M., Bastakis M., Tsopanoglou N. Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties. Kidney Int. 43:1993;147-150.
47. Maragoudakis M.E., Haralabopoulos G.C., Tsopanoglou N.E., Pipili-Synetos E. Validation of collagenous protein synthesis as an index for angiogenesis with the use of morphological methods. Microvasc. Res. 50:1995;215-222.
48. Marneros A.G., Olsen B.R. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol. 20:2001;337-345.
49. McCawley L.J., Matrisian L.M. Matrix metalloproteinases. they're not just for matrix anymore! Curr. Opin. Cell Biol. 13:2001;534-540.
50. Miner J.H., Sanes J.R. Molecular and functional defects in kidneys of mice lacking collagen α3(IV). implications for Alport syndrome J. Cell Biol. 135:1996;1403-1413.
51. Monestiroli S., Mancuso P., Burlini A., Pruneri G., Dell'Agnola C., Gobbi A., Martinelli G., Bertolini F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 61:2001;4341-4344.
52. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin. a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell. 79:1994;315-328.
53. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin. an endogenous inhibitor of angiogenesis and tumor growth Cell. 88:1997;277-285.
54. Ortega N., Werb Z. New functional roles for non-collagenous domains of basement membrane collagens. J. Cell Sci. 115:2002;4201-4214.
55. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., Choi N.C., Mathisen D., Wain J., Mark E.J.et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 296:2002;1883-1886.
56. Paulsson M. Basement membrane proteins. structure, assembly, and cellular interactions Crit. Rev. Biochem. Mol. Biol. 27:1992;93-127.
57. Petitclerc E., Boutaud A., Prestayko A., Xu J., Sado Y., Ninomiya Y., Sarras M.P. Jr., Hudson B.G., Brooks P.C. New functions for Non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J. Biol. Chem. 275:2000;8051-8061.
58. Polette M., Thiblet J., Ploton D., Buisson A.C., Monboisse J.C., Tournier J.M., Birembaut P. Distribution of α1(IV) and α3(IV) chains of type IV collagen in lung tumours. J. Pathol. 182:1997;185-191.
59. Pozzi A., Moberg P.E., Miles L.A., Wagner S., Soloway P., Gardner H.A. Elevated matrix metalloprotease and angiostatin levels in integrin α1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. USA. 97:2000;2202-2207.
60. Pozzi A., LeVine W.F., Gardner H.A. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene. 21:2002;272-281.
61. Prockop D.J., Kivirikko K.I. Collagens. molecular biology, diseases, and potentials for therapy Annu. Rev. Biochem. 64:1995;403-434.
62. Reddy G.K., Gunwar S., Kalluri R., Hudson B.G., Noelken M.E. Structure and composition of type IV collagen of bovine aorta. Biochim. Biophys. Acta. 1157:1993;241-251.
63. Reynolds L.E., Wyder L., Lively J.C., Taverna D., Robinson S.D., Huang X., Sheppard D., Hynes R.O., Hodivala-Dilke K.M. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat. Med. 8:2002;27-34.
64. Rodriguez-Manzaneque J.C., Lane T.F., Ortega M.A., Hynes R.O., Lawler J., Iruela-Arispe M.L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA. 98:2001;12485-12490.
65. Stacker S.A., Achen M.G., Jussila L., Baldwin M.E., Alitalo K. Metastasis. Lymphangiogenesis and cancer metastasis Nat. Rev. Cancer. 2:2002;573-583.
66. Standker L., Schrader M., Kanse S.M., Jurgens M., Forssmann W.G., Preissner K.T. Isolation and characterization of the circulating form of human endostatin. FEBS Lett. 420:1997;129-133.
67. Thyboll J., Kortesmaa J., Cao R., Soininen R., Wang L., Iivanainen A., Sorokin L., Risling M., Cao Y., Tryggvason K. Deletion of the laminin α4 chain leads to impaired microvessel maturation. Mol. Cell. Biol. 22:2002;1194-1202.
68. Timpl R. Macromolecular organization of basement membranes. Curr. Opin. Cell Biol. 8:1996;618-624.
69. Tsilibary E.C., Reger L.A., Vogel A.M., Koliakos G.G., Anderson S.S., Charonis A.S., Alegre J.N., Furcht L.T. Identification of a multifunctional, cell-binding peptide sequence from the α1(NC1) of type IV collagen. J. Cell Biol. 111:1990;1583-1591.
70. Volpert O.V., Zaichuk T., Zhou W., Reiher F., Ferguson T.A., Stuart P.M., Amin M., Bouck N.P. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat. Med. 8:2002;349-357.
71. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., Shapiro S.D., Senior R.M., Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 93:1998;411-422.
72. Yudoh K., Matsui H., Kanamori M., Ohmori K., Tsuji H., Tatezaki S. Serum levels of laminin, type IV collagen and type III procollagen peptide as markers for detection of metastasis. Jpn. J. Cancer Res. 85:1994;1263-1269.
73. Yurchenco P.D., O'Rear J.J. Basal lamina assembly. Curr. Opin. Cell Biol. 6:1994;674-681.
74. Zeisberg M., Bonner G., Maeshima Y., Colorado P., Muller G.A., Strutz F., Kalluri R. Renal fibrosis. collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation Am. J. Pathol. 159:2001;1313-1321.
75. Zhang X., Hudson B.G., Sarras M.P. Jr. Hydra cell aggregate development is blocked by selective fragments of fibronectin and type IV collagen. Dev. Biol. 164:1994;10-23.